Celcuity
- Market cap
- 3.22B
- P/E (TTM)i
- -15.30
- P/Bi
- -252.03
- EPSi
- -3.79
- Div yieldi
- 0.00%
- 52W posi
- 20%
Anonymous reader poll. Unscientific, not investment advice.
Valuation each multiple against its own 5-year range
Vs. peers Biotechnology
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Celcuity (CELC) | 3.22B | -15.30 | -252.03 | 0.00% |
| Vertex Pharmaceuticals (VRTX) | 128.16B | 29.45 | 6.33 | 0.00% |
| Moderna (MRNA) | 78.44B | -24.62 | 11.60 | 0.00% |
| Regeneron Pharmaceuticals (REGN) | 76.40B | 18.36 | 2.41 | 0.49% |
| argenx SE (ARGX) | 58.39B | 35.37 | 6.94 | 0.00% |
| Revolution Medicines (RVMD) | 43.05B | -22.65 | 16.52 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 12.9% below Morningstar's fair value estimate.
Fair value
Celcuity Inc receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a price consistent with our quantitative fair value estimate, which has a very high uncertainty rating.
The firm's balance sheet bolsters our fair value estimate. Low leverage mitigates financial risk, potentially boosting a firm's value. For example, the firm's current ratio of 8.9 ranks in the top 10% compared with global peers. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our balanced fair value estimate.
Conversely, the firm's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of -0.4%, a core component of valuation, ranks in the bottom 10% compared with peers globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which further promotes our neutral price/fair value ratio.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is fairly-valued, this outperformance had a negative impact on our valuation estimate.
Economic moat
With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-10-08 07:00:00 · For reference only, not investment advice and not tailored to your situation.